We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
- Recent CLNN Stock Price: $1.81
- Yearly Gain for CLNN stock: -75.25%
- Market Cap for CLNN stock: $110.49M
- P/E Ratio for CLNN stock: 8.691
Will CLNN's stock price go up? Is there an accurate CLNN stock forecast available?
TipRanks.com reports that Clene currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.67. The target pricing ranges from a high CLNN forecast of $16.00 down to a low forecast of $4.00. Clene (CLNN)’s last closing stock price was $1.81 which would put the average price target at 379.01% upside.
In addition, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CLNN stock.
Other analysts covering CLNN include:
- Naz Rahman of Maxim Group issued a Buy rating with the price target of $ 4 on 2 days ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 16 on 2 days ago
- Elemer Piros of Roth Capital issued a Buy rating with the price target of $ 17 on 4 months ago
If you are wondering if CLNN is a good stock to buy, here are 3rd party ratings for CLNN stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 24% (61 out of 251)
What is the sentiment on the street regarding Clene? (Current ratings compiled by TipRanks.com)
- News Sentiment for CLNN stock: Very Bullish
- Blogger Consensus for CLNN stock: Bullish
- Media Buzz for CLNN stock: High
- Insider Signal for CLNN stock: Positive
- Investor Sentiment for CLNN stock: Very Negative
- Hedge Fund signal for CLNN stock: No Signal
The stock market is extremely volatile, and you need to do your own research on CLNN stock including scouring the social networks like CLNN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CLNN stock chart >>
Summary: Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
- Recent ALNY Stock Price: $201.02
- Yearly Gain for ALNY stock: 1.46%
- Market Cap for ALNY stock: $24.15B
- P/E Ratio for ALNY stock: -24.645
Will ALNY's stock price go up? Is there an accurate ALNY stock forecast available?
TipRanks.com reports that Alnylam Pharma currently has 20 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $236.68. The target pricing ranges from a high ALNY forecast of $430.00 down to a low forecast of $138.00. Alnylam Pharma (ALNY)’s last closing stock price was $201.02 which would put the average price target at 17.74% upside.
In addition, TradingView issued a Neutral rating for ALNY stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALNY stock.
Other analysts covering ALNY include:
- David Lebovitz of Citigroup issued a Buy rating with the price target of $ 280 on 2 days ago
- Gary Nachman of BMO Capital issued a Hold rating with the price target of $ 200 on 2 days ago
- Zhiqiang Shu of Berenberg Bank issued a Hold rating with the price target of $ 184 on 2 days ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $ 250 on 2 weeks ago
If you are wondering if ALNY is a good stock to buy, here are 3rd party ratings for ALNY stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 24% (61 out of 251)
What is the sentiment on the street regarding Alnylam Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALNY stock: Neutral
- Blogger Consensus for ALNY stock: Bullish
- Media Buzz for ALNY stock: Low
- Insider Signal for ALNY stock: n/a
- Investor Sentiment for ALNY stock: Very Positive
- Hedge Fund signal for ALNY stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ALNY stock including scouring the social networks like ALNY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALNY stock chart >>
Summary: Prometheus Biosciences Inc. is a biotechnology company. It involved in the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease. Prometheus Biosciences Inc. is based in SAN DIEGO.
- Recent RXDX Stock Price: $59.48
- Yearly Gain for RXDX stock: 142.15%
- Market Cap for RXDX stock: $2.44B
- P/E Ratio for RXDX stock: -18.907
Will RXDX's stock price go up? Is there an accurate RXDX stock forecast available?
TipRanks.com reports that Prometheus Biosciences currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $64.00. The target pricing ranges from a high RXDX forecast of $74.00 down to a low forecast of $50.00. Prometheus Biosciences (RXDX)’s last closing stock price was $59.48 which would put the average price target at 7.60% upside.
In addition, TradingView issued a Buy rating for RXDX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RXDX stock.
Other analysts covering RXDX include:
- Jeff Jones of Oppenheimer issued a Buy rating with the price target of $ 65 on 2 days ago
- Julian Harrison of BTIG issued a Buy rating with the price target of $ 74 on 3 days ago
- Derek Archila of Wells Fargo issued a Buy rating with the price target of $ 71 on 1 month ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 67 on 1 month ago
If you are wondering if RXDX is a good stock to buy, here are 3rd party ratings for RXDX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 24% (61 out of 251)
What is the sentiment on the street regarding Prometheus Biosciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for RXDX stock: Neutral
- Blogger Consensus for RXDX stock: n/a
- Media Buzz for RXDX stock: Medium
- Insider Signal for RXDX stock: n/a
- Investor Sentiment for RXDX stock: Very Positive
- Hedge Fund signal for RXDX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on RXDX stock including scouring the social networks like RXDX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RXDX stock chart >>
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
- Recent ICPT Stock Price: $14.06
- Yearly Gain for ICPT stock: -2.29%
- Market Cap for ICPT stock: $579.49M
- P/E Ratio for ICPT stock: -6.472
Will ICPT's stock price go up? Is there an accurate ICPT stock forecast available?
TipRanks.com reports that Intercept Pharma currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $24.00. The target pricing ranges from a high ICPT forecast of $49.00 down to a low forecast of $14.00. Intercept Pharma (ICPT)’s last closing stock price was $14.06 which would put the average price target at 70.70% upside.
In addition, TradingView issued a Sell rating for ICPT stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT stock.
Other analysts covering ICPT include:
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $ 35 on 2 days ago
- Thomas Smith of SVB Securities issued a Hold rating with the price target of $ 17 on 2 days ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $ 15 on 5 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 49 on 5 days ago
If you are wondering if ICPT is a good stock to buy, here are 3rd party ratings for ICPT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 24% (61 out of 251)
What is the sentiment on the street regarding Intercept Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ICPT stock: Very Bullish
- Blogger Consensus for ICPT stock: Bearish
- Media Buzz for ICPT stock: Medium
- Insider Signal for ICPT stock: n/a
- Investor Sentiment for ICPT stock: Positive
- Hedge Fund signal for ICPT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ICPT stock including scouring the social networks like ICPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ICPT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================